Next Article in Journal
Genomic Analyses Identify Novel Molecular Signatures Specific for the Caenorhabditis and other Nematode Taxa Providing Novel Means for Genetic and Biochemical Studies
Next Article in Special Issue
Retinogenesis of the Human Fetal Retina: An Apical Polarity Perspective
Previous Article in Journal
To Trim or Not to Trim: Effects of Read Trimming on the De Novo Genome Assembly of a Widespread East Asian Passerine, the Rufous-Capped Babbler (Cyanoderma ruficeps Blyth)
Previous Article in Special Issue
Molecular Strategies for RPGR Gene Therapy

Molecular Therapies for Choroideremia

Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford OX3 9DU, UK
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK
Author to whom correspondence should be addressed.
Genes 2019, 10(10), 738;
Received: 31 July 2019 / Revised: 14 September 2019 / Accepted: 20 September 2019 / Published: 23 September 2019
(This article belongs to the Special Issue Molecular Therapies for Inherited Retinal Diseases)
Advances in molecular research have culminated in the development of novel gene-based therapies for inherited retinal diseases. We have recently witnessed several groundbreaking clinical studies that ultimately led to approval of Luxturna, the first gene therapy for an inherited retinal disease. In parallel, international research community has been engaged in conducting gene therapy trials for another more common inherited retinal disease known as choroideremia and with phase III clinical trials now underway, approval of this therapy is poised to follow suit. This chapter discusses new insights into clinical phenotyping and molecular genetic testing in choroideremia with review of molecular mechanisms implicated in its pathogenesis. We provide an update on current gene therapy trials and discuss potential inclusion of female carries in future clinical studies. Alternative molecular therapies are discussed including suitability of CRISPR gene editing, small molecule nonsense suppression therapy and vision restoration strategies in late stage choroideremia. View Full-Text
Keywords: choroideremia; gene therapy; REP1; inherited retinal disease; treatment choroideremia; gene therapy; REP1; inherited retinal disease; treatment
Show Figures

Figure 1

MDPI and ACS Style

Cehajic Kapetanovic, J.; Barnard, A.R.; MacLaren, R.E. Molecular Therapies for Choroideremia. Genes 2019, 10, 738.

AMA Style

Cehajic Kapetanovic J, Barnard AR, MacLaren RE. Molecular Therapies for Choroideremia. Genes. 2019; 10(10):738.

Chicago/Turabian Style

Cehajic Kapetanovic, Jasmina, Alun R. Barnard, and Robert E. MacLaren. 2019. "Molecular Therapies for Choroideremia" Genes 10, no. 10: 738.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop